 |
|
Heart Outcomes Prevention Evaluation–The Ongoing Outcomes Study, Vitamin E, and Age-Related Macular Degeneration
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In a recent editorial regarding the use of vitamin E for age-related macular degeneration, Chew and Clemons stated:
For these reasons, combined with little evidence from the meta-analysis of harm at the 400 IU/d dosage, we do not think there is increased risk of mortality associated with the AREDS [Age-Related Eye Disease Study] supplements that include 400 IU/d of vitamin E.1
Further, last year I questioned the use of high doses of vitamins E and C because of a study that showed that high doses were associated with heart disease in women.2 The response from Ferris and Milton3 was that the doses were higher than those used in the AREDS. Ferris and Milton also stated:
We know of no clear indication of increased risk of cardiovascular disease with the doses of vitamins C or E used in AREDS or in patients similar to the AREDS population.3
I wonder whether Chew . . . [Full Text of this Article]
AUTHOR INFORMATION
Jose S. Pulido, MD
RELATED LETTER
Heart Outcomes Prevention Evaluation–The Ongoing Outcomes Study, Vitamin E, and Age-Related Macular Degeneration—Reply
Emily Y. Chew and Traci E. Clemons
Arch Ophthalmol. 2006;124(11):1665-1666.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Vitamin E and the Age-Related Eye Disease Study Supplementation for Age-Related Macular Degeneration
Emily Y. Chew and Traci Clemons
Arch Ophthalmol. 2005;123(3):395-396.
EXTRACT
| FULL TEXT
|
